While fewer people died from malaria in 2015 than in years past, the rate of progress against the disease has slowed. Read more...
MVI PortfolioWe strategically use our resources to support and advance a range of vaccine approaches that target both humoral and cellular immunity.
Evaluation technology projectsWe partner to develop and optimize new assays and challenge models and support reference and service laboratories. Find out more about our evaluation technologies by clicking on each project box below.
RTS,SThe World Health Organization (WHO) recommends pilot implementations for GSK's malaria vaccine candidate RTS,S (also known as MosquirixTM).